In a new study from the USC Stem Cell lab of Rong Lu, PhD , researchers used genetic barcoding to track individual human blood-forming stem and progenitor cells after transplanting them into mice. The study revealed how different types of human blood-forming cells regenerate the blood and immune system, and how different forms of pre-transplant conditioning, treatment used to prepare a recipient before bone marrow transplantation, affected blood and immune cell recovery. The findings, just published in npj Regenerative Medicine , add to the scientific understanding of human blood and immune cell regeneration and can inform future strategies to optimize bone marrow transplants for patients.
Researchers used genetic barcode-based clonal tracking, which allows them to follow individual cells and their descendants to see how they contribute to blood and immune cell production over time, comparing two cell types: hematopoietic stem cells (HSCs) and multipotent progenitor cells (MPPs). Both HSCs and MPPs can produce multiple types of blood and immune cells, but HSCs are thought to have unique long-term regenerative capacity, based largely on animal studies.
"We found that human HSCs and MPPs don't always behave as we would expect based on previous studies in mice," said Rong Lu, PhD , professor of stem cell biology and regenerative medicine at the Keck School of Medicine of USC , who led the research. She is also a professor of biomedical engineering, medicine and gerontology. "Our findings underscore the importance of studying human cells directly to understand how they function in the context of transplantation."
The study, supported by the National Institutes of Health, is one of the first to systematically examine how human HSCs and MPPs respond to various forms of pretransplant conditioning, including chemotherapy and radiation, and contribute to the production of blood and immune cells. Down the line, it could support the development of more effective and personalized approaches to bone marrow transplantation, which is used to treat blood cancers such as leukemia and lymphoma and certain inherited blood disorders.
Stem cells and transplant treatments
For the study, first author Mary Vergel Snodgrass and her colleagues transplanted human HSCs or MPPs into mice, then used clonal tracking to compare how the two cell populations contributed to blood and immune cell production over time.
They found that both HSCs and MPPs produced multiple types of blood and immune cells over an extended period after transplantation, suggesting that human MPPs may have greater long-term regenerative capacity than previously observed in mouse studies. However, HSCs generally produced more blood cells and were better at producing multiple types of blood and immune cells than MPPs.
The researchers also compared several approaches to transplant conditioning, which helps reduce a recipient's own stem and progenitor cells and makes room for donor cells. Mice received either radiation treatment, chemotherapy with the drug busulfan, or no conditioning treatment. The conditioning approach influenced how many and which types of blood and immune cells were produced, and how quickly blood cell production occurred, without significantly affecting donor cell engraftment in the bone marrow.
"We also found that HSCs were less affected by conditioning, while MPPs were more sensitive, shifting the types of immune cells they produced. This suggests that human HSCs can maintain more consistent blood and immune cell production under different transplantation conditions," Lu said.
These findings could eventually help clinicians tailor pre-transplant treatments to individual patients, supporting more effective blood and immune cell recovery while minimizing treatment-related complications. While further studies are needed to determine how these findings translate to patients, they could help guide the development of safer and more effective transplantation strategies.
New insights into human blood cell regeneration
In a final experiment, the researchers transplanted HSCs and MPPs from the initial recipients into a second group of mice to test their long-term regenerative capacity. They found that both cell types continued producing blood and immune cells, but at substantially lower levels.
They also made an unexpected discovery: In mice that received a second transplant, blood cell production occurred not only in the bone marrow but also in other tissues, including the spleen, which became substantially enlarged. Lu noted that this phenomenon has also been observed in human diseases and may indicate that the mouse bone marrow environment does not fully support human blood cell production.
Next, Lu and her team are investigating how blood-forming stem cells communicate with surrounding bone marrow cells to regulate blood and immune cell regeneration. This work could help explain why different conditioning treatments lead to different patterns of blood and immune cell recovery.
About this research
In addition to Lu and Vergel Snodgrass, the study's other authors are Jiya Eerdeng, Patrick Condie and Basia Gala from the Department of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine of USC and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC.
This work was supported by the National Institutes of Health (grant R35HL150826). Additional support came from a USC Provost's Fellowship; California Institute for Regenerative Medicine training grant (EDUC4-12756); and a Leukemia & Lymphoma Society scholarship (LLS-1370-20).